Bloomberg ID:  CCSC130 <Equity>       Morningstar ID:  F00000V3XE

The Constantia Capital Small-Cap Biotech+ Strategy is a passively managed strategy that aims to match the returns of Biotechnology, Life Sciences and Medical Device stocks in the Russell 2000.


Biotech+ stocks have excellent growth potential, buoyed by new discoveries. These Small-cap publicly traded stocks are highly levered to the success of their drugs and devices undergoing clinical trials. Demand from large-cap pharmaceuticals to fill their pipelines increases potential returns by way of mergers and acquisitions.

Support for Biotech Stocks in 2021
Recent Research in Biotech Stocks
* Live Inception Date: January 31, 2020;
   backtest prior to Inception Date.

Performance Summary to February 28, 2021, Net of Fees (50 bps)

Constantia Logo-white-04.png

Constantia Capital, LLC

17 Hendrickson Rd, Suite 100
Lawrenceville, NJ 08648



  • LinkedIn Social Icon

Content © 2013-2021 Constantia Capital, LLC.  All rights reserved.  Registered in New Jersey, New York, and Pennsylvania.
Past performance is not a guarantee of future results.  Strategies involve risk of loss of principal.